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Nyaditum resae (NR) is a galenic preparation of heat-killed Mycobacterium manresensis
(hkMn). This is a new species that belongs to the Mycobacterium fortuitum complex, and
it is present in drinking water—thus, regulatorily speaking, it is considered a food
supplement.
Preclinical studies in the murine model of active tuberculosis (TB) in the C3HeB/FeJ strain
have demonstrated that daily administration of NR containing 103–106 hkMn for 14 days
was able to stop the progression toward active TB [1]. The mechanism of action was linked
to the induction of low dose tolerance andwas related to the increase of Tuberculin Purified
Protein Derivative (PPD) memory-specific Tregs (CD4+CD25+CD39+ cells) after ex vivo incu-
bation of splenocytes for 7 days. This increase of Tregs was related to the increase of inter-
leukin (IL)-10 in the spleen and in the reduction of IL-17 in the lungs, where there was also
a reduction in bacillary load and the pathology caused by a reduction of neutrophiles’
infiltration [2].
Two randomized, double-blind placebo-controlled clinical trials (CTs) have been con-
ducted in humans. The NYADATREG study (Clinicaltrials.gov identifier NCT02076139;
2013–2014) was aimed to evaluate the safety and the immunogenicity of two concentra-
tions of NR (containing 104 hkMn and 105 hkMn) versus placebo (all administered orally
everyday for 14 days) in tuberculin-positive and tuberculin-negative volunteers (total
n = 51). The results demonstrated an excellent safety record, with no differences between
groups in terms of adverse effects. A significant increase in PPD-specific memory regulatory
T cells was also detected in both NR groups [3]. The NYADAPETRICS study (Clinicaltrials.gov
identifier NCT02581579) is evaluating the safety and immunogenicity of NR 105 hkMn (cap-
sule format, orally) in the pediatric population. Currently, an efficacy study (randomized,
double-blinded, placebo-controlled CT) is being conducted in Georgia. This NYADAGEORG
trial includes close contacts of active TB cases with positive sputum not tributaries of
chemoprophylaxis (<5-year-old children and HIV-positive individuals), which will receive
NR (containing 105 hkMn) or placebo (orally, every day for 14 days). A total of 3300 partici-nia, Spain.
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tuberculosis development. Int. J. Mycobacteriopants will be recruited in four medical centers around Tbilissi. The participants are moni-
tored by telephone for up to 2 years to evaluate the incidence of active TB. The hypothesis is
that the NR group will exhibit a 40% reduction in expected TB incidence. Thus, the antici-
pated TB incidence will be 3% in the NR group versus 5% in the placebo group. The CT is
projected to end by 2021 (Clinicaltrials.gov identifier NCT02897180).
The administration of the food supplement NR appears to be a new, easy, safe, and reli-
able method for reducing the risk of developing active TB, and new CTs must be encour-
aged to discern the particular efficacy power according to different population
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